OWC Pharmaceutical Research Corp. Reports the Successful Production of Its Cannabinoid-Enriched Sublingual Disintegrating Tablet

RAMAT GAN, Israel, Dec. 18, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reports the successful production of its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as smoking substitute.    

Smoking and inhalation are currently the most common using methods of administering medical cannabis. However, the precise concentration of active cannabinoids in inflorescences is inconsistent and difficult to determine. In addition, smoking may have deleterious side effects and social acceptance issues, which may reduce compliance of drug administration. "OWCP's sublingual disintegrating tablet will offer an alternative to smoking and inhalation, allowing for controlled, consistent dosing and diligent compliance to medical regimens and offer quick pain and other symptoms relief as Sublingual absorption provides a direct route for cannabis to enter much quicker to the blood system," said Mordechai Bignitz, CEO at OWC Pharmaceutical Research Corp.

OWCP now reports that it has completed the successful production of its sublingual tablet, which will allow the company to begin its clinical testing program for this dosing form. OWCP has received an IRB approval to conduct a pharmaco-kinetic (PK) safety study of its sublingual tablet. In addition, OWCP has applied for an amendment to its study protocols to enable the comparison of its tablet with a known cannabis-based pharmaceutical, which is registered for treatment of spasticity in Multiple Sclerosis patients. The company has also received a permit from the IMCA (Israel Medical Cannabis Agency) to conduct an efficacy study of the tablet on chronic pain syndrome.  

The studies will be conducted at the Sourasky Academic Medical Center in Tel Aviv and are expected to start in the first quarter of 2019. Tel Aviv Sourasky Medical Center is the largest acute care facility in Israel, treating about 400,000 patients and hosting 1.8 million patient visits per year. A 1500-bed world-class governmental academic medical center, Tel Aviv Sourasky Medical Center serves a population of one million people, including residents from the greater Tel Aviv area and visitors to the metropolis.

About OWC Pharmaceutical Research Corp

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.

Contact:
Mordechai Bignitz
Chief Executive Officer
OWC Pharmaceutical Research Corp.
[email protected]
Tel: +972-(72)-260-8004

SOURCE OWC Pharmaceutical Research Corp.

Related Links

http://owcpharma.com/